https://www.selleckchem.com/pr....oducts/cct251545.htm
Background Cryptococcal antigen (CrAg) screening for antiretroviral therapy (ART)-naïve adults with advanced HIV/AIDS can reduce the incidence of cryptococcal meningitis (CM) and all-cause mortality. We modeled the cost-effectiveness of laboratory-based "reflex" CrAg screening for ART-naïve CrAg-positive patients with CD4 less then 100 cells/µL (those currently targeted in guidelines) and ART-experienced CrAg-positive patients with CD4 less then 100 cells/µL (who make up an increasingly large proportion of individuals with advanced HI
Like
Comment
Share
